enasidenib

Also known as AG-221, CC-90007, 2-Methyl-1-(4-(6-(trifluoromethyl)pyridin-2-yl)-6-(2-(trifluoromethyl)pyridin-4-ylamino)-1,3,5-triazin-2-ylamino)propan-2-ol

Enasidenib, sold under the brand name Idhifa, is an anti-cancer medication used to treat relapsed or refractory acute myeloid leukemia. It is an inhibitor of isocitrate dehydrogenase 2 (IDH2).

In the Vinony graph

Within Vinony's link graph, enasidenib is referenced by 278 other articles, and connects out to chemotherapy, tiazofurin and International Standard Book Number.

It is catalogued under topics including Antineoplastic drugs, Chemicals using indexlabels and Disubstituted pyridines.

Its subject is documented across 7 Wikipedia language editions.

Chemical data

Formula: C19H17F6N7O
Molecular weight: 473.4 g/mol
IUPAC name: 2-methyl-1-[[4-[6-(trifluoromethyl)-2-pyridinyl]-6-[[2-(trifluoromethyl)-4-pyridinyl]amino]-1,3,5-triazin-2-yl]amino]propan-2-ol
SMILES: CC(C)(CNC1=NC(=NC(=N1)C2=NC(=CC=C2)C(F)(F)F)NC3=CC(=NC=C3)C(F)(F)F)O
InChIKey: DYLUUSLLRIQKOE-UHFFFAOYSA-N
XLogP: 3.5
Polar surface area: 109 Å²
H-bond donors: 3
H-bond acceptors: 14
Formal charge: 0

via PubChem

Wikidata facts

Subclass of: chemical compound
Mass: 473.139878
Has use: medication

Show 5 more facts

chemical formula: C₁₉H₁₇F₆N₇O
canonical SMILES: CC(C)(CNC1=NC(=NC(=N1)NC2=CC(=NC=C2)C(F)(F)F)C3=NC(=CC=C3)C(F)(F)F)O
NCI Thesaurus ID: C111573
medical condition treated: acute myeloid leukemia
Commons category: Enasidenib

Sources (4)

via Wikidata · CC0

~3 min read

Encyclopedic overview

7 sections

Contents

Medical use
Adverse effects
History
Society and culture
Legal status
References
External links

Enasidenib, sold under the brand name Idhifa, is an anti-cancer medication used to treat relapsed or refractory acute myeloid leukemia. It is an inhibitor of isocitrate dehydrogenase 2 (IDH2).

Common side effects of enasidenib include nausea, vomiting, diarrhea, increased levels of bilirubin (substance found in bile), and decreased appetite. Women who are pregnant or breastfeeding should not take enasidenib because it may cause harm to a developing fetus or a newborn baby.

Excerpted from Wikipedia’s “enasidenib” article, available under the CC BY-SA 4.0 licence.